SGCG and type 2 diabetes mellitus: This imbalance-together with small discovery samples (notably the T2DM discovery set)-may have biased shared-gene discovery toward the strongest, most coherent programs (type I IFN/ISGs) while impeding detection of weaker but biologically relevant overlaps, including potential type II/type III interferon-related pathways.